Salinosporamides and methods of use thereof

US10314818B2 · kind B2 · utility

Assignee

• The Regents of the University of California · US

Inventors

• William Fenical · Del Mar, US
• Paul Jensen · San Diego, US
• Tracy Mincer · San Diego, US
• Robert H. R. Feling · Wiesbaden, DE

Key dates

• Filing date: Jul 20, 2017
• Grant date: Jun 11, 2019
• Expiry date: Jul 28, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12P17/188
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.